Status:
UNKNOWN
Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
Lead Sponsor:
Shandong Cancer Hospital and Institute
Conditions:
Radiation Toxicity
Advanced Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Despite the common application of radiotherapy in cancer treatment, the prediction of radiosensitivity and treatment response has not yet entered the era of precision medicine. Therefore, development ...
Detailed Description
Researchers have long recognized that individual differences in sensitivity to radiation are caused by genetic variations and implicated multiple key pathways that might explain radiation toxicity. No...
Eligibility Criteria
Inclusion
- Patients with locally advanced solid tumors (lung cancer, esophageal cancer, rectal cancer (neoadjuvant), cervical cancer, nasopharyngeal carcinoma cancer and liver cancer) identified by cytology and pathology;
- Patients need conventional fractionation and adequate radiotherapy;
- Age ≥ 18 years old, male and female;
- Expected survival time ≥ 12 weeks;
- PS score 0-2 within 2 weeks before admission to the group;
- There are tumor tissue samples and blood samples can be used for NGS inspection;
- Patients volunteered to join this study, sign informed consent, provide all diagnosis and treatment data after cancer diagnosis before entering the group, good compliance, cooperate with follow-up.
Exclusion
- The patient's previous radiation therapy leads to overlapping potential fields;
- Stage IV patients and stage I patients to be treated with SBRT
- The patient cannot receive regular imaging examinations;
- Any serious or uncontrolled signs of systemic disease that the investigator believes may significantly affect the patient's risk/benefit balance, including hepatitis B, hepatitis C, and human immunodeficiency virus;
- The researcher believes that it is not suitable for the group.
Key Trial Info
Start Date :
October 8 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 8 2021
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04110223
Start Date
October 8 2018
End Date
October 8 2021
Last Update
October 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong Cancer Hospital and Institute
Jinan, Shandong, China, 250117